Metabolic alterations driven by PFKFB3 upregulation confer resistance to trastuzumab in HER2-positive breast cancer
PFKFB3 upregulation drives metabolic adaptations that confer resistance to trastuzumab in HER2 + breast cancer. These findings highlight PFKFB3 as a promising therapeutic target to overcome resistance and improve patient outcomes.
Authors
- Mark M. Moasser (ORCID: https://orcid.org/0000-0003-4411-4336)
- Danny Huylebroeck (ORCID: https://orcid.org/0000-0003-4862-1079)
- Veronica Steri (ORCID: https://orcid.org/0000-0003-2499-6618)
- Roos Vincken
- Ana Ruiz-Sáenz (ORCID: https://orcid.org/0000-0001-6033-6153)
- Samuel T. Pasco (ORCID: https://orcid.org/0000-0002-4276-4098)
- Wilfred F. J. van IJcken (ORCID: https://orcid.org/0000-0002-0421-8301)
- A. Carracedo
- Laura Bozal-Basterra
Institutions
- University of California, San Francisco (US)
- Erasmus MC (NL)
- CIC bioGUNE (ES)
- UCSF Helen Diller Family Comprehensive Cancer Center (US)
- Erasmus University Rotterdam (NL)
Publication Details
- Journal
- Biomedicine & Pharmacotherapy
- Published
- 2026-01-01
- DOI
- https://doi.org/10.1016/j.biopha.2025.118898
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00